SRR1797262
— · cohortSC
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSC
- subtype
- cohortSC
- age_years
- 51
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.510
- E2F_TARGETS+0.370
- SPERMATOGENESIS+0.310
- G2M_CHECKPOINT+0.230
- MYC_TARGETS_V1+0.180
- DNA_REPAIR+0.150
- UV_RESPONSE_UP+0.130
- KRAS_SIGNALING_DN+0.070
- MTORC1_SIGNALING+0.020
- HEDGEHOG_SIGNALING+0.010
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- INTERFERON_ALPHA_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.410
- TNFA_SIGNALING_VIA_NFKB-0.400
- NOTCH_SIGNALING-0.390
- IL6_JAK_STAT3_SIGNALING-0.370
- INFLAMMATORY_RESPONSE-0.370
- ANDROGEN_RESPONSE-0.360
- PROTEIN_SECRETION-0.360
- ALLOGRAFT_REJECTION-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR13780251 | — | cohortSC | 0.932 |
| 2 | MDT-AP-1165 | Med | Medulloblastoma | 0.901 |
| 3 | TCGA-C4-A0EZ-01A-21R-A24X-07 | — | — | 0.893 |
| 4 | BS_W9AT0MR7 | medulloblastoma | — | 0.891 |
| 5 | BS_ERWT0ZWE | medulloblastoma | — | 0.889 |
| 6 | TCGA-BT-A2LA-01A-11R-A18C-07 | — | — | 0.889 |
| 7 | BS_WH5HDE0A | medulloblastoma | — | 0.889 |
| 8 | BS_ZXYDSBM9 | medulloblastoma | — | 0.888 |
| 9 | BS_Z45HD492 | medulloblastoma | — | 0.886 |
| 10 | SRR1797255 | — | cohortSC | 0.886 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.510 | Cobimetinib | — uncovered |
| E2F_TARGETS | 0.370 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.130 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.020 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.010 | Inavolisib | — uncovered |